Vaxart, Inc. (VXRT) stock

VXRTOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 10/30

$0.48+0.02 (+5.04%)

Close on Oct 19, 2026Market cap $115.61MP/E 4.0Yield –

Vaxart price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Vaxart's price to sales ratio was 0.5× on Oct 19, 2026, against 0.9× a year earlier. Over the last 5 years it ranged from 0.4× to 490.0×, with a median of 13.9×.

Price to Sales Ratio at the end of each year

Period	Period end	Value	Change (pts)
2026	Oct 19, 2026	0.5×	−0.1
2025	Dec 31, 2025	0.5×	−8.5
2024	Dec 31, 2024	9.0×	−11.9
2023	Dec 29, 2023	20.9×	−469.1
2022	Apr 29, 2022	490.0×	+16.7
2021	May 28, 2021	473.3×	+391.1
2020	Dec 31, 2020	82.2×	+80.1
2019	Dec 31, 2019	2.1×	+0.7
2018	Dec 31, 2018	1.4×	−24.6
2017	Dec 29, 2017	26.1×	−30.2
2016	Dec 30, 2016	56.2×	+24.0
2015	Dec 31, 2015	32.2×	+17.1
2014	Dec 31, 2014	15.1×	−23.8
2013	Dec 31, 2013	38.9×	−10.0
2012	Dec 31, 2012	48.9×	–